Reviewing Castle Biosciences (CSTL) & The Competition

Castle Biosciences (NASDAQ:CSTL – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it compare to its peers? We will compare Castle Biosciences to related companies based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Castle Biosciences and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences 1 1 8 1 2.82
Castle Biosciences Competitors 1881 7755 13400 834 2.55

Castle Biosciences presently has a consensus price target of $46.50, indicating a potential upside of 38.94%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.84%. Given Castle Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Castle Biosciences is more favorable than its peers.

Valuation and Earnings

This table compares Castle Biosciences and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Castle Biosciences $344.23 million -$24.16 million -43.46
Castle Biosciences Competitors $21.21 billion $301.67 million -1.79

Castle Biosciences’ peers have higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Castle Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Castle Biosciences -6.10% -4.89% -4.06%
Castle Biosciences Competitors -7.86% -135.43% -1.59%

Risk & Volatility

Castle Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Castle Biosciences’ peers have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Summary

Castle Biosciences beats its peers on 8 of the 13 factors compared.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.